Discover educational opportunities to sharpen your knowledge and build essential skills to succeed in your medical practice. For state- and specialty-specific educational content, please visit our Resources for curated content.
AMA Ed Hub™
Designed to support lifelong learning, licensure and certification needs, the AMA Ed Hub offers high-quality education to physicians and other medical professionals who seek to stay current and continuously improve the care they provide.
Resources
Online CME Module: Stigma in Methadone and Buprenorphine Maintenance Treatment
This module describes the history of methadone maintenance and the effectiveness and key myths of opioid agonist treatment, explores empathizing with patients taking methadone or buprenorphine, and empowers clinicians to support patients and their significant others.
The ASAM Treatment of Opioid Use Disorder Course
This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. ASAM also provides the additional 16 hours that are required for NPs and PAs
The ASAM Fundamentals of Addiction Medicine Resources
The resources presented are meant to be a general guide to the materials available for primary care physicians and clinicians on addiction related topics.
Pain Management & Opioids: Balancing Risks & Benefits – Updated (2.5 CME)
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018.